A detailed history of Prospera Financial Services Inc transactions in Incyte Corp stock. As of the latest transaction made, Prospera Financial Services Inc holds 3,788 shares of INCY stock, worth $267,205. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,788
Previous 6,710 43.55%
Holding current value
$267,205
Previous $406,000 38.42%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$57.33 - $68.61 $167,518 - $200,478
-2,922 Reduced 43.55%
3,788 $250,000
Q2 2024

Aug 13, 2024

BUY
$51.18 - $63.75 $76,155 - $94,860
1,488 Added 28.49%
6,710 $406,000
Q1 2024

Aug 13, 2024

SELL
$56.55 - $66.59 $8,991 - $10,587
-159 Reduced 2.37%
6,551 $373,000
Q4 2023

Feb 14, 2024

BUY
$52.16 - $64.19 $49,343 - $60,723
946 Added 22.12%
5,222 $327,000
Q3 2023

Nov 13, 2023

BUY
$57.77 - $65.93 $635 - $725
11 Added 0.26%
4,276 $247,000
Q2 2023

Aug 08, 2023

BUY
$60.95 - $75.51 $9,691 - $12,006
159 Added 3.87%
4,265 $265,000
Q1 2023

May 12, 2023

BUY
$70.23 - $86.01 $9,059 - $11,095
129 Added 3.24%
4,106 $296,000
Q4 2022

Feb 08, 2023

BUY
$67.18 - $84.11 $40,039 - $50,129
596 Added 17.63%
3,977 $319,000
Q3 2022

Oct 27, 2022

BUY
$66.18 - $82.86 $28,457 - $35,629
430 Added 14.57%
3,381 $225,000
Q2 2022

Aug 08, 2022

SELL
$66.18 - $83.18 $23,229 - $29,196
-351 Reduced 10.63%
2,951 $224,000
Q1 2022

May 04, 2022

BUY
$66.02 - $79.71 $217,998 - $263,202
3,302 New
3,302 $262,000
Q4 2020

Feb 12, 2021

SELL
$80.74 - $97.7 $3,148 - $3,810
-39 Closed
0 $0
Q3 2020

Nov 04, 2020

BUY
$85.07 - $109.69 $3,317 - $4,277
39 New
39 $3,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.7B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Prospera Financial Services Inc Portfolio

Follow Prospera Financial Services Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prospera Financial Services Inc with notifications on news.